Abstract | BACKGROUND: METHODS: RESULTS: Here, we report that the continuous administration of STR-324 significantly reduced mechanical allodynia and spontaneous pain-related behavior from day 2 to day 7 in animals that received 10 or 50 µg/h of STR-324 as compared to placebo-treated animals (P < .00001 and P < .0011, respectively, for mechanical allodynia; P = .028 and P = .0049, respectively, for spontaneous pain-related behavior). In addition, STR-324 reduced the pain-evoked expression of spinal c-Fos in this model, demonstrating that it acts at least in part through inhibition of endogenous nociceptive pathways. CONCLUSIONS: These observations suggested that STR-324 may be an effective addition to the multimodal approach for treating clinical neuropathic pain.
|
Authors | Alain Van Elstraete, Philippe Sitbon, Leila Hamdi, Victor Juarez-Perez, Jean-Xavier Mazoit, Dan Benhamou, Catherine Rougeot |
Journal | Anesthesia and analgesia
(Anesth Analg)
Vol. 126
Issue 6
Pg. 2102-2111
(06 2018)
ISSN: 1526-7598 [Electronic] United States |
PMID | 28806211
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Oligopeptides
- Salivary Proteins and Peptides
- glutaminyl-arginyl-phenylalanyl-seryl-arginine
|
Topics |
- Administration, Intravenous
- Animals
- Disease Models, Animal
- Hyperalgesia
(drug therapy, metabolism, pathology)
- Male
- Neuralgia
(drug therapy, metabolism, pathology)
- Oligopeptides
(administration & dosage, chemistry)
- Pain Measurement
(drug effects, methods)
- Rats
- Rats, Sprague-Dawley
- Salivary Proteins and Peptides
(administration & dosage, chemistry)
|